Gritstone Oncology, Inc. is a biotechnology company focused on the development of innovative immunotherapies for cancer treatment. Utilizing its proprietary Gritstone’s EDGE platform, the company aims to discover and develop personalized cancer vaccines and adoptive T cell therapies. Gritstone's pipeline includes programs targeting multiple cancer types, with a strong emphasis on the immune system's role in fighting tumors. The company is committed to unlocking the potential of the immune system to improve patient outcomes through its unique approaches to cancer treatment.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

6 Patents

#81 in Emeryville, CA

#10,583 in California

#45,030 in US

Emeryville, CA, United States of America

Gritstone Oncology, Inc.

Forward Citations = 10

16 inventors:

Roman Yelensky (5 out of 35 patents)

Brendan Bulik-Sullivan (3 out of 6 patents)

Adnan Derti (3 out of 4 patents)

4. Jennifer Busby (3 out of 5 patents)

5. Karin Jooss (3 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gritstone Oncology, Inc.. Retrieved from https://idiyas.com/company/gritstone-oncology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]